


### 4th Quarter 2023 Report (October 1 - December 31)

Percent change evaluated relative to 4th Quarter 2022

#### Summary

- The percentage of prescribers enrolled in the PDMP system has stayed consistent compared to the 4th quarter of 2022 (*Table 1 and Figure 1*).
- Total gateway automated queries decreased (-5.1%) while reports viewed through integration increased (19.4%). Overall web queries decreased (-3.3%) compared to Q4 2022.
- Overall, the total number of prescriptions for controlled substances have increased (3.0%) since the 4th quarter of 2022. Gabapentin is the most prescribed substance in the system with a slight increase (1.1%) in prescriptions over the last year. While most other top prescriptions decreased, oxycodone, methylphenidate, and testosterone prescriptions increased (*Table 5*).



- *Figure 1* shows the percentage of prescribers enrolled in the PDMP over time from 2013-2023. Registration has remained consistent since 2018.

Table 1. PDMP Enrollment and System Use for Oregon Prescribers<sup>1</sup>: October 1 - December 31, 2023.

User Type	Prescribers	Enrolled	Web Query	Automated Query*	Total Query*
All Prescribers (by DEA)	19,270	16,641 (86.4%)	2,614 (15.7%)	12,813 (77.0%)	13,268 (79.7%)
Top 4,000 Prescribers	4,000	3,930 (98.3%)	1,350 (34.4%)	3,555 (90.5%)	3,702 (94.2%)
Top 2,000 Prescribers	2,000	1,973 (98.7%)	791 (40.1%)	1,801 (91.3%)	1,889 (95.7%)

<sup>1</sup>Counts provided by unique DEA number, but providers may have multiple DEA numbers.

- Controlled substances were prescribed by 19,270 Oregon providers in the 4th quarter of 2023.
- During the 4th quarter, 79.7% of enrolled prescribers, 94.2% of the top 4,000 prescribers, and 95.7% of the top 2,000 prescribers queried using the web portal and/or gateway integration.
- The percentage of enrolled prescribers who querying has decreased since the 4th quarter of 2022 when 83.0% of enrolled prescribers submitted queries.

Table 2. Special Requests: October 1 - December 31, 2023.

Measure	Count
Patient Records	15
Healthcare Boards	31
Law Enforcement	1
<b>Total Special Requests</b>	<b>47</b>

- 47 special requests were received and processed by PDMP staff.
- Healthcare boards were the most frequent originators of these requests.

Table 3. PDMP Activity Summary Statistics: October 1 – December 31, 2023.

User Type	Web Portal		Gateway Integration			
	Queries	% Change <sup>1</sup>	Automated Queries <sup>2</sup>	% Change <sup>1</sup>	Reports Viewed <sup>2</sup>	% Change <sup>1</sup>
Healthcare providers	82,519	0.4%	5,420,786	-6.4%	911,836	27.2%
Pharmacies	73,761	-18.2%	1,203,424	1.8%	658,358	10.1%
Delegates	156,870	3.6%	-	-	-	-
<b>Total Queries<sup>2</sup></b>	<b>313,226</b>	<b>-3.3%</b>	<b>6,624,210</b>	<b>-5.1%</b>	<b>1,570,194</b>	<b>19.4%</b>

<sup>1</sup>Percent change evaluated relative to same time period during the prior year.

<sup>2</sup>Query data drawn from Appriss AWARe web portal, PMPi Gateway audit file and EDIE supplementary audit file. Queries de-duplicated using last name, date of birth, prescriber ID, and date of query

- Web portal usage overall decreased by 3.3%, with pharmacies decreasing usage by -18.2%.
- Gateway automated queries decreased, largely driven by the 6.4% decrease in queries by healthcare providers. Gateway reports viewed increased by 19.4% over Q4 2022.

Table 4. Query by Clinical User Group for Enrolled Providers: October 1 - December 31, 2023.

Discipline	Total Accounts (by DEA) <sup>1</sup>	% Change <sup>2</sup>	Web Users <sup>3</sup>	% Change <sup>2</sup>	Integrated Users <sup>3</sup>	% Change <sup>2</sup>
MD/PA/DO	20,710	10.6%	1,630	-2.1%	13,900	-5.7%
NP/CNS-PP	5,177	13.3%	1,144	11.3%	3,428	-3.0%
RPh	3,589	16.6%	1,363	3.9%	495	19.9%
Delegates	3,434	18.6%	1,786	0.5%	NA	NA
DDS/DMD	2,841	9.8%	329	-8.6%	312	23.8%
ND	714	33.5%	163	5.8%	375	-19.4%

<sup>1</sup>Counts provided by unique DEA Number, but providers may be associated with multiple DEA numbers.

<sup>2</sup>Percent change evaluated relative to same quarter during the prior year.

<sup>3</sup>Query data drawn from Appriss AWARe web portal, PMPi Gateway audit file and EDIE supplementary audit file. Queries de-duplicated using last name, date of birth, prescriber ID, and date of query.

- Table 4 represents usage for providers who are registered in the PDMP.
- In general, enrollment for all disciplines increased with continuing use of PDMP through the web portal. Web portal queries have increased from the same quarter last year across most user groups, with the largest increase in the NP/CNS-PP disciplines. Integration usage was mixed.

Table 5. Top Prescriptions: October 1 - December 31, 2023.

Drug	Number of Rx	% of all Rx	% Change
All	1,687,403	100%	3.0%
Gabapentin	235,973	14.0%	1.1%
Oxycodone	226,162	13.4%	0.9%
Amphetamine	205,714	12.2%	-0.2%
Hydrocodone	205,335	12.2%	-5.7%
Methylphenidate	96,607	5.7%	11.7%
Lorazepam	79,710	4.7%	-1.6%
Tramadol	74,079	4.4%	-3.4%
Zolpidem	58,949	3.5%	-4.1%
Testosterone	57,294	3.4%	12.2%
Alprazolam	55,588	3.3%	-3.7%

- Gabapentin remains the top prescribed drug with prescriptions increasing 1.1% relative to the 4<sup>th</sup> quarter of 2022, while hydrocodone decreased 5.7%. Oxycodone prescriptions slightly increased (0.9%).
- Commonly prescribed benzodiazepines decreased (i.e., lorazepam and alprazolam), while prescriptions for the stimulant, methylphenidate increased by 11.7%, relative to the same quarter last year.
- Gabapentin is the top prescribed drug (14% of all prescriptions) in the PDMP. The addition of gabapentin as a PDMP-covered substance was effective as of January 1st, 2020.

---

**Contact: PDMP Research Analyst, [pdmp.research@odhsoha.oregon.gov](mailto:pdmp.research@odhsoha.oregon.gov)**

---